ClinicalTrials.gov
public full text
Public Domain
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease#979962
- Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation#665245
- Interest to Perform a Renal Biopsy Early in the Course of the Henoch-Schoenlein Nephritis#909335
- Lanreotide In Polycystic Kidney Disease Study#1152310
- Enalapril in Collagen Type 4 Nephropathy#858554
Record · ID 903944
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive